GlassScriptPhysician profile
Alia M Anthony
NPI 1023557634
$2,352.76
in general payments reported to CMS, 2019-2025
25 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.72 · 2023: $76.80 · 2024: $1,109 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.84 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $353.19 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $307.54 | 2024-2025 | |
| Abbvie INC. | $149.33 | 2023-2025 | |
| Glaxosmithkline, LLC. | $105.16 | 2024-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $100.29 | 2024-2025 | Veozah |
| Amgen INC. | $96.36 | 2023-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $91.72 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $82.63 | 2024-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $81.22 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.31 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $67.78 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $62.79 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.86 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $55.89 | 2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $54.92 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $36.76 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $32.11 | 2024 | Voquezna |
| Ucb, INC. | $23.78 | 2024 | Nayzilam |
| Sumitomo Pharma America, INC. | $23.45 | 2024 | Gemtesa |
| Neurelis, INC. | $21.59 | 2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $19.24 | 2024 | Austedo Xr |
| Esperion Therapeutics, INC. | $17.76 | 2025 | Nexletol |
| Electromed, INC. | $17.62 | 2025 | Smartvest |
| Inspire Medical Systems, INC. | $15.62 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alia Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.